Emerging revolutionary treatments for spinal muscular atrophy (SMA) require a fast diagnosis. Also, SMA carrier screening is recommended for all women considering pregnancy. It’s challenging for laboratories to provide timely and comprehensive information for diagnosis and carrier screening. We’re working to ensure labs can quickly provide comprehensive information on SMN1 and SMN2. This video premiered at the 2021 ASHG annual meeting.

Back To

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.